Cosopt Versus Xalatan

Phase 4

Completed

• Conditions: Open-Angle Glaucoma; Ocular Hypertension

• Registration Number: NCT00273429
• Lead Sponsor: Pharmaceutical Research Network

Brief Summary

To compare the 24-hour efficacy and safety, measured every three hours, of the dorzolamide/timolol fixed combination given twice daily versus latanoprost and placebo each given once daily.

Detailed Description

Not available

Study Timeline

• Study Start: 2005-04
• Study Completion: 2005-12
• Study First Submitted: 2006-01-06
• Study First Submitted QC: 2006-01-06
• Study First Posted: 2006-01-09
• Status Verified: 2007-01
• Last Update Submitted: 2007-01-08
• Last Update Posted: 2007-01-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• adults with primary open-angle, pigmentary, or exfoliation glaucoma, or ocular hypertenstion
• intraocular pressure should be 22 to 30 mm Hg inclusive on timolol BID at the 08:00 H
• ETDRS visual acuity must be 1.0 or better in both eyes

Exclusion Criteria

• any contraindications to study medications
• any anticipated change in systemic hypertensive therapy during the trial

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Trial Locations

Locations (2)

Midwest Eye Center SC; 🇺🇸 Bourbonnais, Illinois, United States

Central Florida Eye Associates; 🇺🇸 Lakeland, Florida, United States